Background: Fecal calprotectin (FC) is widely used to discriminate between patients with inflammatory diseases such as inflammatory bowel disease (IBD) and functional diseases such as irritable bowel syndrome (IBS). ELISA is a time-consuming method for the measurement of FC, whereas a fluorescent immunochromatography test can obtain results in around 30 minutes and thus enables a rapid response to clinical decision.
| INTRODUC TI ON
Calprotectin, formed as a heterodimer of S100A8 and S100A9, constitutes about 60% of soluble cytosol proteins in human neutrophil granulocytes. 1 Calprotectin is released by granulocyte activation and elevated level of fecal calprotectin (FC) is found in the GI tract inflammation that closely related to inflammatory bowel disease (IBD) activity. 2, 3 Increasing evidence indicates that FC can be used as a noninvasive marker for intestinal/colonic inflammation that helps clinicians distinguish organic inflammatory bowel disease (IBD) from functional irritable bowel syndrome (IBS). [4] [5] [6] Markers of systemic inflammation, such as C-reactive protein (CRP) and white blood cells count, have low specificity and sensitivity for IBD, while the gold standard of ileo-colonoscopy is invasive and expensive. 3 Thus, noninvasive method for monitoring disease activity is preferable. FC is more sensitive than serum CRP in reflecting disease activity in IBD 7 and can be used to identify patients at risk of relapse and predict both endoscopic and histological mucosal healing. 8 Fecal calprotectin testing in laboratories may require stool samples transportation from outpatient departments to the laboratory. Furthermore, enzyme-linked immunosorbent assay (ELISA) is a timeconsuming method for the measurement of FC, with a turnaround time of about 1 to 2 weeks, which may interfere with timely medical treatment and raise the risk of disease deterioration before clinical treatment, 9 whereas a fluorescent immunochromatography test achieves a shorter turnaround time (around 30 minutes) and thus enables a rapid response to clinical decision. The study was aimed to evaluate the consistency of two methods in the determination of FC concentrations.
| MATERIAL S AND ME THODS

| Sample collection and storage
A total of 111 stool samples were collected from 111 different participants (only one sampling was done from each patient), who were treated in a tertiary hospital, Beijing Tsinghua Changgung Hospital (BTCH, Beijing, China), from September to October 2018. Out of the 111 participants, 99 were confirmed IBD patients and 12 were healthy controls. After collection, the samples were stored in the −20℃ refrigerator until tested and frozen and thawed only once.
Samples with insufficient size, samples contaminated, and samples without traceable information were excluded. FC concentrations of the 111 stool samples were parallelly detected by the Proglead ® calprotectin method (FC Proglead) and the BÜHLMANN fCAL ® ELISA method (FC BÜHLMANN).
| Stool sample extraction
Stool sample extraction could be achieved using two different methods. The first method was a stool weighing-based extraction protocol, and the second method was the use of the stool extraction device. 10 To simplify stool extraction, collected stool samples were all extracted using a commercially available fecal extraction devices (CALEX ® Cap Device) before testing for calprotectin by two methods.
Briefly, stool sample preparation is diluted with extraction buffer and mixed well. Vortex the CALEX ® Cap Device vigorously on a vortex mixer for 30 seconds and let the samples equilibrate for at least 5 minutes. Centrifuge the CALEX ® Cap for 5 minutes at 3000 g. Take the supernatant into a fresh, labeled tube and continue with parallel testing by FC Proglead and FC BÜHLMANN methods for each stool sample. FC BÜHLMANN method was a commercially available ELISA method. 11 Stool extraction prepared following procedures described in 2.2 section was parallelly tested by FC BÜHLMANN method for each stool sample following instructions provided. Briefly, the supernatant was incubated at room temperature onto a 96-well plate coated with a capture antibody. After incubation of 30 minutes, washing, a second incubation of 30 minutes with a detection antibody conjugated to horseradish peroxidase (HRP), and a further washing step, tetramethylbenzidine (blue color formation) followed by a stop solution (change to yellow color) were added. The absorption was determined at an optical density of 450 nm. 12 The same lot of reagent was used for both methods throughout the study. Two levels of quality control materials were used for quality control for both methods to ensure the reliability of the results.
| Calprotectin measurement
| Statistical analysis
Clinical & Laboratory Standards Institute EP09C protocol was implemented for the method comparison and bias estimation of FC concentrations by two methods. 13 It indicated that FC results distribution were skewed leftward, medians were calculated, and biases were evaluated by Wilcoxon signed rank test. And, deming regression was employed to calculate the slope, intercept, and correlation coefficient. Percent biases at FC cutoff values (50 and 200 μg/g) between both methods were determined using three regression models, and percent biases were compared with the acceptable standard (10%, derived from the reagent instruction). All the 111 individuals were grouped into low-, moderate-, or high-risk groups by FC cutoff values of <50, 50 to 200, and >200 μg/g, respectively. 12, 14 Kappa statistic was applied to evaluate the risk classification agreement between both methods. Cohen's kappa values (kappa) <0.20, 0.21 to 0.39, 0.40 to 0.59, 0.60 to 0.79, 0.80 to 0.90, and >0.90 were interpreted as none, minimal, weak, moderate, strong, and almost perfect agreement, respectively. 15 A two-tailed P value of <.05 was judged to be statistically signifi- Figure 1 and Table 1 . Table 2 . Table 3 .
| RE SULTS
| Correlation and regression analysis
| Method comparison and bias analysis
| Agreement evaluation
| D ISCUSS I ON
Patients with IBD often have increased calprotectin concentrations in blood or feces samples. 9, 16 FC is used to distinguish IBD from IBS.
FC has been analyzed by ELISA methods, such as BÜHLMANN fCAL ® ELISA (Bühlmann Laboratories AG). 17 Although ELISA method offers accurate quantitative measurements, it is processed in a batch-like procedure (once or twice a week) increasing the turnaround time and requiring high expertise. 10 20 the estimated median bias and percent bias between two methods (FC Proglead − FC BÜHLMANN) were −4.19 μg/g and −8.71%, respectively. These biases were acceptable in clinical practice. 21 Less than 5% of the points was outside the 95% limits of agreement. Different FC cutoff values to distinguish IBD from IBS have been reported. FC cutoff values were reported in the range of 150-250 µg/g. 22, 23 Percent bias at FC cutoff values of 50 and 200 μg/g between both methods was simultaneously estimated using three regression models; 22,24 these differences were all less than the acceptable standard (10%). The agreement study demonstrated that 99.10% (110/111) of the individuals were classified into the same group between both methods (kappa = .99, P < .001).
Overall, this study proposes that FC results of FC Proglead are in good agreement with that of FC BÜHLMANN and FC Proglead may be used as a suitable alternative to FC BÜHLMANN for the gastrointestinal inflammation activity assessment for patients with IBD.
FC Proglead method could significantly shorten the reporting turnaround time and enable timely response to patients, thus potentially improve treatment quality.
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